Altimmune (ALT)
(Delayed Data from NSDQ)
$7.20 USD
-0.59 (-7.57%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $7.20 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Altimmune, Inc. [ALT]
Reports for Purchase
Showing records 1 - 20 ( 77 total )
Company: Altimmune, Inc.
Industry: Medical - Drugs
End-of-Phase 2 Meeting With the FDA on Track for 3Q24; Partnering Discussions Underway
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Altimmune, Inc.
Industry: Medical - Drugs
1Q24 Results; Partnering Discussion Underway Ahead of Endof-Phase 2 Meeting With the FDA in 3Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Altimmune, Inc.
Industry: Medical - Drugs
Lean Mass Data Further Differentiates Pemvidutide Ahead of Phase 3; HepTcell Discontinued; Lowering PT to $12; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Altimmune, Inc.
Industry: Medical - Drugs
Hepatitis B Breakthrough Boom: Navigating a $450-$500 Billion Frontier
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Altimmune, Inc.
Industry: Medical - Drugs
Pemvidutide Well-Positioned in GLP-1 Race; Collaboration Discussions Underway Ahead of Phase 3; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Altimmune, Inc.
Industry: Medical - Drugs
Pemvidutide Shines in Obesity, Differentiating From Approved GLP-1 Agents; Phase 3 Study Expected in 2024; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Altimmune, Inc.
Industry: Medical - Drugs
Positive Read-Through From Phase 1b Trial in NAFLD Bodes Well For Pemvidutide in NASH and Obesity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Altimmune, Inc.
Industry: Medical - Drugs
3Q23 Results; Phase 2 Data in Obesity on Track for 4Q23; FDA and Partner Discussions on Lead Compounds Expected in 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Altimmune, Inc.
Industry: Medical - Drugs
HBV and NASH Conference Takeaways: Lead Programs HepTcell and Pemvidutide Advancing to Key Near-Term Readouts; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Altimmune, Inc.
Industry: Medical - Drugs
Company: Altimmune, Inc.
Industry: Medical - Drugs
Pemvidutide Obesity Phase 2 Data Expected 4Q23; Lowering Price Target to $15 on GLP-1 Competitive Dynamics
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Altimmune, Inc.
Industry: Medical - Drugs
1Q23 Results; Pipeline Progressing; MOMENTUM Phase 2 Obesity Data on Track for 4Q23; NASH Phase 2b Trial Imminent
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Altimmune, Inc.
Industry: Medical - Drugs
MOMENTUM Interim Analysis Keeps Pemvidutide on Track for Phase 3 in Obesity and Phase 2b in NASH; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Altimmune, Inc.
Industry: Medical - Drugs
4Q22 Earnings; MOMENTUM Obesity Data Expected Second Half of March; NASH Program Progressing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Altimmune, Inc.
Industry: Medical - Drugs
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Altimmune, Inc.
Industry: Medical - Drugs
Bright Spotlight on Pemvidutide Ahead of MOMENTUM Obesity Interim Analysis Expected 1Q23; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Altimmune, Inc.
Industry: Medical - Drugs
A Management Breakfast Event During the 2023 JPM Healthcare Conference in San Francisco
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Altimmune, Inc.
Industry: Medical - Drugs
After Compelling Data in 12-Week Extension NAFLD Trial, Attention Shifts to MOMENTUM Obesity Data in 1Q23; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Altimmune, Inc.
Industry: Medical - Drugs
Reiterate Buy Ahead of Phase 1b NAFLD and Phase 2 Obesity Pemvidutide Datasets Expected Near-Term
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Altimmune, Inc.
Industry: Medical - Drugs
Selloff Following Pemvidutide Phase 1b NAFLD Data Release Creates Compelling Buying Opportunity Ahead of Obesity Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P